USA- Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved its SCS system which is designed to treat multi-site and evolving pain.
The system, allows doctors to modify the programming in response to the patient’s changing demands and provides pain coverage in up to six regions.
Abbott now has a new strategy to pursue after receiving FDA permission which is to grow its market share in the spinal cord stimulation industry, where it competes with Boston Scientific, Medtronic, and Nevro.
Proclaim Plus expands on the elements Abbott created to set apart its spinal cord stimulator.
The device employs FlexBurst360, an upgraded form of Abbott’s BurstDR stimulation that sends electrical energy packets at higher frequencies and smaller amplitudes than conventional tonic stimulation.
It also makes use of connected care technology and a 10-year, recharge-free battery.
BurstDR treatment is a proprietary stimulation method developed by Abbott that uses brief bursts of moderate electrical energy to modulate pain signals as they pass from the spinal cord to the brain.
Clinical research has demonstrated that BurstDR technology provides superior pain relief when compared to tonic stimulation3, enhances people’s daily lives, and lessens the emotional distress brought on by pain.
At Abbott, we are deeply committed to advancing the field of neurostimulation, thus helping people address the challenges they face while managing their chronic pain.
In the United States, more than 50 million people experience chronic pain, and 88% of them experience pain in at least two or more separate parts of their bodies.
SCS therapy often referred to as neurostimulation, is a form of implanted technology that modifies how the body processes pain signals by sending modest electrical pulses to the nerves that run along the spinal cord.
This treatment can reduce chronic pain and enhance the quality of life. The U.S. Pain Foundation estimates that chronic pain accounts for the majority of doctor visits and that it costs the country US$635 billion annually in lost productivity, disability, and medical expenses.
Steven Falowski, M.D., Argires Marotti Neurosurgical Associates of Lancaster commented that Spinal cord stimulation has provided tremendous relief for patients suffering from chronic pain.
“Now, with Proclaim Plus and FlexBurst360, an already established platform has been improved to treat more patients who suffer from pain across different body parts and changing pain over time,” added Steven.
“At Abbott, we are deeply committed to advancing the field of neurostimulation, thus helping people address the challenges they face while managing their chronic pain,” said Pedro Malha, vice president, neuromodulation, Abbott.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
